Boston Scientific (NYSE:BSX) PT Raised to $90.00 at UBS Group

Boston Scientific (NYSE:BSX) had its target price boosted by investment analysts at UBS Group from $74.00 to $90.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage presently has a “buy” rating on the medical equipment provider’s stock. UBS Group’s price target suggests a potential upside of 23.07% from the company’s current price.

BSX has been the subject of several other research reports. StockNews.com cut Boston Scientific from a “buy” rating to a “hold” rating in a report on Saturday, March 16th. Citigroup lifted their price target on shares of Boston Scientific from $71.00 to $79.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Wells Fargo & Company lifted their target price on shares of Boston Scientific from $72.00 to $82.00 and gave the company an “overweight” rating in a research report on Thursday. BTIG Research reaffirmed a “buy” rating and set a $64.00 price objective on shares of Boston Scientific in a report on Friday, December 29th. Finally, Mizuho boosted their price target on Boston Scientific from $80.00 to $85.00 and gave the company a “buy” rating in a research note on Thursday. Three research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $75.09.

Boston Scientific Trading Down 0.2 %

Boston Scientific stock opened at $73.13 on Thursday. The firm has a market capitalization of $107.29 billion, a PE ratio of 61.45, a PEG ratio of 2.48 and a beta of 0.78. The business’s 50-day simple moving average is $67.82 and its 200-day simple moving average is $60.51. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.82 and a current ratio of 1.32. Boston Scientific has a 52 week low of $48.35 and a 52 week high of $74.39.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, January 31st. The medical equipment provider reported $0.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.51 by $0.04. The business had revenue of $3.73 billion for the quarter, compared to analyst estimates of $3.59 billion. Boston Scientific had a net margin of 12.06% and a return on equity of 16.63%. During the same quarter in the previous year, the firm posted $0.45 earnings per share. Equities research analysts forecast that Boston Scientific will post 2.32 earnings per share for the current year.

Insider Activity at Boston Scientific

In other Boston Scientific news, CFO Daniel J. Brennan sold 13,662 shares of Boston Scientific stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $65.86, for a total transaction of $899,779.32. Following the completion of the sale, the chief financial officer now owns 271,542 shares of the company’s stock, valued at approximately $17,883,756.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CFO Daniel J. Brennan sold 13,662 shares of the firm’s stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $65.86, for a total value of $899,779.32. Following the transaction, the chief financial officer now directly owns 271,542 shares in the company, valued at approximately $17,883,756.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Edward J. Ludwig sold 7,000 shares of Boston Scientific stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $65.03, for a total value of $455,210.00. Following the sale, the director now directly owns 41,374 shares of the company’s stock, valued at $2,690,551.22. The disclosure for this sale can be found here. Insiders have sold 50,979 shares of company stock worth $3,418,529 over the last ninety days. Company insiders own 0.50% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. IFP Advisors Inc raised its holdings in Boston Scientific by 29.1% in the third quarter. IFP Advisors Inc now owns 5,026 shares of the medical equipment provider’s stock worth $265,000 after purchasing an additional 1,132 shares during the period. Private Trust Co. NA increased its position in shares of Boston Scientific by 498.8% in the 3rd quarter. Private Trust Co. NA now owns 5,132 shares of the medical equipment provider’s stock valued at $271,000 after buying an additional 4,275 shares in the last quarter. Czech National Bank raised its stake in Boston Scientific by 50.4% during the 3rd quarter. Czech National Bank now owns 255,916 shares of the medical equipment provider’s stock worth $13,512,000 after buying an additional 85,706 shares during the period. Blue Fin Capital Inc. grew its stake in Boston Scientific by 19.9% in the third quarter. Blue Fin Capital Inc. now owns 8,024 shares of the medical equipment provider’s stock valued at $424,000 after acquiring an additional 1,334 shares during the period. Finally, WS Portfolio Advisory LLC bought a new stake in shares of Boston Scientific in the third quarter worth about $5,056,000. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.